A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

Shares fell 75% to $3.04, putting the stock on track for a record closing low, according to Dow Jones Market Data. The stock ...

Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...

Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] ...

"BikeTown Africa," a nonprofit organization, delivered more than 200 bikes to rural Africa to provide life-saving and ...

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...